Anti-Rheumatic Drugs - United Kingdom

United Kingdom

The United Kingdom's Anti-Rheumatic Drugs market is estimated to generate a revenue of €0.74bn in 2024.
It is predicted that the market will experience a compound annual growth rate (CAGR 2024-2029) of 1.82%, leading to a market volume of €0.81bn by 2029.
In terms of global comparison, United States is expected to generate the highest revenue in the market, reaching €32,180.00m in 2024.
The United Kingdom has seen a rise in the demand for biologic anti-rheumatic drugs, as patients seek more targeted and effective treatment options.

Key regions: Germany, United States, India, Japan, United Kingdom

Mercado

Región

Comparación de regiones

Moneda

Analyst Opinion

The Anti-Rheumatic Drugs market in United Kingdom has been growing steadily over the past few years.

Customer preferences: Patients suffering from rheumatoid arthritis and osteoarthritis are the primary customers of anti-rheumatic drugs in the United Kingdom. These patients prefer drugs that offer effective pain relief and improve joint mobility. Additionally, they also prefer drugs that have fewer side effects and are easy to administer.

Trends in the market: One of the major trends in the Anti-Rheumatic Drugs market in United Kingdom is the increasing use of biologic drugs. Biologic drugs are more effective in reducing inflammation and offer better disease control compared to traditional disease-modifying antirheumatic drugs (DMARDs). Another trend is the increasing use of combination therapy, where biologic drugs are used in combination with DMARDs to achieve better disease control.

Local special circumstances: The National Institute for Health and Care Excellence (NICE) is responsible for providing guidance on the use of drugs in the United Kingdom. NICE has recommended the use of biologic drugs in the treatment of rheumatoid arthritis and psoriatic arthritis, which has led to an increase in their use. However, the high cost of these drugs has limited their availability to only a small number of patients.

Underlying macroeconomic factors: The United Kingdom has an ageing population, which is a major factor driving the growth of the Anti-Rheumatic Drugs market. As people age, the incidence of rheumatoid arthritis and osteoarthritis increases, leading to an increase in demand for anti-rheumatic drugs. Additionally, the United Kingdom has a well-established healthcare system that provides access to these drugs to a large number of patients. However, the high cost of these drugs has put pressure on the healthcare system, leading to a need for cost-effective treatment options.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.